According to FutureWise analysis the chronic kidney disease diagnostics market in 2025 is US$ 1.28 billion, and is expected to reach US$ 2.11 billion by 2033 at a CAGR of 6.45%. The global rise in diabetes and hypertension, major risk factors for chronic kidney disease (CKD), is increasing the demand for early diagnostic solutions. Innovations in biomarker tests and point-of-care diagnostics are enhancing the early detection and monitoring of kidney function.
Chronic kidney disease (CKD) often presents with subtle symptoms that may go unnoticed by patients, such as blood in the urine, swollen joints, and foamy urine. This lack of awareness can lead to a progressive decline in kidney function, ultimately culminating in renal failure if not addressed in a timely manner. The challenges associated with CKD are further compounded by factors such as delayed diagnosis, the scarcity of comprehensive epidemiological data, and the significant financial burden associated with managing end-stage renal diseases and even the earlier stages of the condition.
Given these challenges, there is a pressing need for improved diagnostics for chronic kidney disease. In addition to thorough physical examinations by healthcare professionals, various diagnostic tools are critical in identifying potential kidney issues early on. These tools include kidney biopsies, which can provide a cellular-level understanding of kidney health, as well as routine blood and urine tests, which reveal important markers related to kidney function, electrolyte balance, and overall organ health.
Healthcare professionals can leverage the insights gained from these diagnostic evaluations to implement effective management strategies tailored to individual patients. By addressing kidney symptoms proactively and monitoring disease progression, clinicians can significantly improve patient outcomes and potentially halt the advance of chronic kidney disease. Early intervention is key to preserving kidney function and enhancing the quality of life for those affected by this condition.
Factors boosting the chronic kidney disease diagnostics market:
• Rising prevalence of kidney diseases
• Increase in diabetic patients’ population
• Investments into R D for kidney diseases diagnostic techniques
• The ever-emerging healthcare sector
• Extensive use of processed food containing excess potassium and
• The technological advancements in the healthcare diagnostics sector
Besides increased susceptibility of the ageing population due to degrading immune system, diabetics, cardiovascular issues are expected to fuel the growth of the global chronic kidney diseases diagnostics market during the forecast period.
Emergence of Novel Biomarkers: Traditional biomarkers such as serum creatinine and estimated glomerular filtration rate (eGFR) are being supplemented by new biomarkers that provide more accurate early detection of chronic kidney disease (CKD). These new tools include urinary biomarkers and multi-omics approaches that enhance diagnostic precision.
Integration of Artificial Intelligence (AI): AI-driven diagnostic tools are being developed to analyze complex datasets, including imaging and genetic information, to predict the progression of CKD and personalize treatment plans.
FutureWise Market Research has published a report that provides an insightful analysis of Chronic Kidney Disease Diagnostics Market trends that are affecting the overall market growth.

Request a Free Sample @ https://www.futurewiseresearch.com/contact.aspx?rpt=137&type=requestsample
Chronic Kidney Disease Diagnostics Market Segmentation:
By Product Type
• By Diagnosis
o Blood Tests
o Urine Tests
o Imaging Tests
o Others
• By Treatment
o Drug Class
 ACE Inhibitors
 Angiotensin-II Receptor Blockers
 Diuretics
 Other
o Dialysis
o Other

By End-User
• Hospitals
• Clinics
• Diagnostic labs

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape in Chronic Kidney Disease Diagnostics Market:
• Abbott Laboratories
• AbbVie Inc.
• Amgen Inc.
• Beckman Coulter
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline Plc
• Pfizer Inc
• Siemens Healthineers
• Sysmex Corporation
• Teva Pharmaceutical Industries Ltd

Recent developments by key players in Chronic Kidney Disease Diagnostics Market:

Abbott Laboratories
Abbott’s Afinion™ ACR assay, used on the Afinion 2 System, provides a quantitative analysis of urinary albumin, creatinine, and the albumin-to-creatinine ratio (uACR) in about 5 minutes, enabling swift identification of early-stage chronic kidney disease (CKD) in patients at high risk, such as those with diabetes or hypertension.

Pfizer Inc
Pacibekitug, a monoclonal antibody targeting IL-6 that was initially licensed from Pfizer, has recently finished its Phase II "TRANQUILITY" trial in patients with chronic kidney disease (CKD) exhibiting increased inflammation. It effectively lowered high-sensitivity CRP levels, making it a potential anti-inflammatory strategy for managing CKD.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=137&license=multi

**Objectives of this Study: **
1. To provide a comprehensive analysis of the Chronic Kidney Disease Diagnostics Market By Product Type, By End-User and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: [email protected]

FutureWise Research
Contact Person: Vinay Thaploo.
Email: [email protected]
Contact Number: Asia: +91 8605575209 | UK: +44 0113 519 7222
Website: www.futurewiseresearch.com